ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02739217
Recruitment Status : Completed
First Posted : April 15, 2016
Last Update Posted : August 29, 2018
Sponsor:
Information provided by (Responsible Party):
ProMetic BioSciences Inc.

Brief Summary:

This is a Phase 2, single-centre, single-arm, open-label study of the safety, tolerability, and effects on biomarkers of PBI-4050 in subjects with Alström syndrome for a treatment duration of 24 weeks.

Subjects who complete the initial 24 weeks of treatment may continue treatment for an additional 36 or 48 weeks, provided the subject signs informed consent.


Condition or disease Intervention/treatment Phase
Inflammation and Fibrosis Diabetes Drug: PBI-4050 Phase 2

Detailed Description:

This is a Phase 2, single-centre, single-arm, open-label study of the safety, tolerability, and effects on biomarkers of PBI-4050 in subjects with Alström syndrome. Approximately 18 subjects will be enrolled. The duration of study participation is approximately 35 weeks for each subject and comprises of 9 on site visits and telephone contacts in between visits.

Subjects who complete the initial 24 weeks of treatment may continue treatment for an additional 36 or 48 weeks (Extension Period [EP]), provided the subject signs informed consent. The extension period includes a further 3 on site visits and telephone contacts in between visits. The total duration of the study participation is extended to approximately 71 or 83 weeks. The Data Safety Monitoring Board (DSMB) will determine if the safety data continue to support treatment for an additional 36 or 48 weeks.

At the completion of the EP End of Treatment, subjects will be allowed to enrol in the Alström Rollover Study PBI-4050-CT-9-10 and continue ongoing study medication without any break in treatment.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of Its Effects on the Inflammatory, Fibrosis, Diabetes and Obesity Biomarkers in Subjects With Alström Syndrome
Actual Study Start Date : February 22, 2016
Actual Primary Completion Date : September 26, 2017
Actual Study Completion Date : June 4, 2018


Arm Intervention/treatment
Experimental: PBI-4050
Four 200 mg capsules (total 800 mg) administered orally, once daily.
Drug: PBI-4050
Four 200 mg capsules (800 mg total) administered orally, once daily.




Primary Outcome Measures :
  1. Description and number of abnormal laboratory values and adverse events that are related to treatment. [ Time Frame: Primary on 24 weeks; Final on all data (including Extension Period) ]

Secondary Outcome Measures :
  1. Change from baseline in metabolic syndrome parameters over time. [ Time Frame: 24 weeks and end of Extension Period ]
    Change from baseline in fasting plasma glucose over time. Change from baseline in fasting plasma insulin over time. Change from baseline in glycated hemoglobin (HbA1c) over time. Change from baseline in Homeostasis Model Assessment for steady state beta cell function (HOMA-B) and insulin sensitivity (HOMA-S) over time.

  2. Change from baseline in biomarkers in blood and urine over time [ Time Frame: 24 weeks and end of Extension Phase ]
    Percentage of reduction and/or increase of level of biomarkers

  3. Change from baseline in cardiac function parameter: NT-proBNP [ Time Frame: 24 weeks and end of Extension Phase ]
  4. Change from baseline of antidiabetic treatment [ Time Frame: 24 weeks and end of Extension Phase ]
    Dosing change, new medication added or treatment discontinuation


Other Outcome Measures:
  1. Changes from baseline in histological appearances in fat biopsies [ Time Frame: 24 weeks and end of Extension Phase ]
    Measuring the degree of fibrosis

  2. Changes from baseline in global metabolome and microdialysate fractions [ Time Frame: 24 weeks and end of Extension Phase ]
  3. Change from baseline in the liver stiffness [ Time Frame: 24 weeks and end of Extension Phase ]
    Measured in kilopascal (kPa) correlated to fibrosis by using a FibroScan

  4. Change from baseline in fat content and fibrosis burden in liver MRI [ Time Frame: 24 weeks and end of Extension Phase ]
  5. Change from baseline in left ventricular ejection fraction in cardiac MRI [ Time Frame: 24 weeks and end of Extension Phase ]
  6. Change from baseline in blood glucose as measured by weekly 4 point profile [ Time Frame: 24 weeks and end of Extension Phase ]
  7. Change from baseline in hyperinsulinaemic-euglycaemic clamp measurements. [ Time Frame: 24 weeks and end of Extension Phase ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria :

  • Subject is 16 years of age or older at screening.
  • Subject has signed informed consent.
  • Subject has a documented diagnosis of Alström syndrome
  • Subject on diabetes treatment has been receiving the same antidiabetic agent(s) for a minimum of 1 month before screening.
  • Subject is able and willing to self-monitor blood glucose level at home or can obtain adequate assistance from care givers.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at screening and agree to use adequate birth control from screening throughout the study and for 30 days after the last Investigational Medicinal Product (IMP) administration. If a male subject has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for 30 days after the last IMP administration.

Exclusion Criteria:

  • Subject has recent or on-going infection requiring systemic treatment with an anti-infective agent within 30 days before screening.
  • Subject has had at least two documented episodes of severe hypoglycaemia within 12 months before screening
  • Subject has uncontrolled hypertension with BP > 170/100 mmHg as determined at screening.
  • Subject has alanine transaminase (ALT) or aspartate transaminase (AST) level ≥ 5 × upper limit of normal (ULN) at screening.
  • Subject is currently using weight loss medications at screening. Subjects may be re-screened after stopping the weight loss medication for a period of at least 5 half-lives.
  • Subject has used any moderate/potent inducer or inhibitor of CYP2C9 isozyme or strong inducer or inhibitor of cytochrome P450 (CYP) 3A isozyme within 30 days prior to the first study drug administration.
  • Subject has a history of chronic alcohol or other substance abuse as determined at screening.
  • Woman who is pregnant, breast-feeding, or planning a pregnancy during the course of the study as determined at screening.
  • Subject has any condition that, in the investigator's opinion, is likely to interfere with study conduct and compliance
  • Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02739217


Locations
United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom, B15 2PR
Sponsors and Collaborators
ProMetic BioSciences Inc.
Investigators
Principal Investigator: Tarekegn Hiwot, MD Queen Elizabeth Hospital Birmingham

Responsible Party: ProMetic BioSciences Inc.
ClinicalTrials.gov Identifier: NCT02739217     History of Changes
Other Study ID Numbers: PBI-4050-ATX-9-05
First Posted: April 15, 2016    Key Record Dates
Last Update Posted: August 29, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Fibrosis
Inflammation
Alstrom Syndrome
Pathologic Processes
Hereditary Sensory and Motor Neuropathy
Nervous System Malformations
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Polyneuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Retinitis Pigmentosa
Eye Diseases, Hereditary
Eye Diseases
Ciliopathies
Abnormalities, Multiple
Congenital Abnormalities
Genetic Diseases, Inborn